HeartBeam : Fourth Quarter 2023 Earnings Conference Call Presentation

The Power of a 12-Lead ECG

Always with the patient

Fourth Quarter & Full Year 2023 Financial Results Conference Call

NASDAQ: BEAT

March 20, 2024

Fourth Quarter 2023 Financial Results Conference Call

DISCLAIMERS

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

HeartBeam AIMIGoTM has not yet been evaluated by the FDA and are not approved for clinical use in the USA or other global geographies.

2

Agenda

Fourth Quarter 2023 Financial Results Conference Call

• Introduction and Company Overview
• AIMIGo Update
• Regulatory Updates
• VALID-ECGClinical Study
• AI Program Updates
• IP Update
• Financial Results
• Closing Summary
• Q&A

Branislav Vajdic, PhD

CEO & Founderv

Rick Brounstein

Consulting CFOv

30 years of experience in technology development and senior management positions. At Intel, he was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs.

30 years of experience in health technology senior management. During his career he has held positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager.

Rob Eno

President

Deborah Castillo, PhD

VP, Regulatory Affairs

28 years of experience with a proven track record of developing markets and commercializing disruptive medical technologies. During his career he has created go-to-market strategies for multiple breakthrough products and held senior marketing and sales leadership roles.

Experienced biomedical engineer with extensive knowledge of Food and Drug Administration (FDA), EU, and Health Canada regulations. She has significant expertise in cardiovascular diseases and neuroscience, and medical devices that support these functions.

3

Fourth Quarter 2023 Financial Results Conference Call

Company

Overview

Branislav Vajdic, PhD

Chief Executive Officer

4

						Fourth Quarter 2023 Financial Results Conference Call
No Heart Attack Solution Practical for Home Use on the Market
		IMPRACTICAL				DO NOT DETECT
		FOR HOME USE				HEART ATTACKS
	TRADITIONAL 12-LEAD ECG			PATIENT-FRIENDLY

Standard 12-lead ECGs

require a health care

professional and are not practical for home use

5

Fourth Quarter 2023 Financial Results Conference Call

HeartBeam AIMIGo: Easy-to-Use Credit Card-Sized 12L ECG

HEARTBEAM AIMIGo:

• First and only credit card-sized12-lead ECG device
• Handheld device with no external electrodes or wires
• Captures heart's signals in 3 projections (X, Y, Z)
• Provides a more complete view of the heart than a standard 12-lead ECG
• Synthesizes a 12-Lead ECG

HeartBeam AIMIGoTM has not yet been evaluated by the FDA and is not yet approved for clinical use in the USA or other global geographies.

6

Fourth Quarter 2023 Financial Results Conference Call

Patients Cannot Determine if They Are Having a Heart Attack

Ignore symptoms

Lost lives

• Patients delay an average of 3 hours before seeking care
• Delays lead to increased mortality
• Greater incidence of heart failure among these patients

Go to Emergency Department

Wasted healthcare dollars

• Chest pain is second most common reason for an ED visit

82 of chest pain ED visits % are unnecessary

Mortality rate increases by

40%

for an average wait of 3-4 hours after symptoms begin

Am I having a heart attack?

$10B	Cost to the
	healthcare system

$ each year

Gibson CM et al J Am Coll Cardiol. 2019 Apr, 73 (15) 1919-1927	7

Fourth Quarter 2023 Financial Results Conference Call

12-Lead ECG is the Standard of Care in Cardiology:

WHY AIMIGo MATTERS

TRANSFORMATIONAL:

AIMIGo makes 12-lead ECG available to patients and their physicians 24/7

IMPACT:

• Ability to take frequent 12-lead ECG recordings over time in various real-life situations is potentially of major diagnostic value
• Trending of 12L ECGs over time - symptomatic and asymptomatic - can yield new insights on cardiac health
• AI applied to longitudinally collected, data-rich VECGs could lead to unsurpassed predictive and diagnostic algorithms

Frequent 12L ECGs has potential to be a new paradigm

8

Fourth Quarter 2023 Financial Results Conference Call

HeartBeam US Market Opportunity

			Potential to address
Total CAD Patients	~20M	Atrial Fibrillation market
		~3M	and
AFib Patients
			6x larger Coronary
MARKET OPPORTUNITY		Artery Disease (CAD)
$14B+	market
• AFib: $2 Billion

• CAD: $12+ Billion

HeartBeam AIMIGoTM has not yet been evaluated by the FDA and is not yet approved for clinical use in the USA or other global geographies.

9

Fourth Quarter 2023 Financial Results Conference Call

AIMIGo

Update

Rob Eno

President

10